

For More Information:

Layna L. Mendlinger
info@vtivision.com

For immediate release

New Data Affecting Myopic Astigmatic Patients: NaturalVue Multifocal demonstrates 100% astigmatic correction up to 2.00 D and 83% to 3.00 D

Visioneering Technologies, Inc. Highlights Astigmatism Correction and Myopia Management Advancements with NaturalVue® Multifocal at GSLS

Las Vegas, Nevada, January 16, 2025: Visioneering Technologies, Inc. (ASX: VTI), maker of NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses, unveiled significant findings at the Global Specialty Lens Symposium (GSLS). The data is from a clinical trial led by Professor Gonzalo Carracedo (Universidad Complutense de Madrid) on astigmatism correction in myopic children and updates from VTI's ongoing PROTECT study.

Astigmatism Study Key Findings:

Presented in a poster session and a presentation titled, *"Evaluation of Visual Acuity with Multifocal Catenary Curve-Based Contact Lens Design in Different Degrees of Astigmatism"*:

- **Astigmatic Vision Correction:**
 - 100% success with astigmatism \leq 2.00 D.
 - 83% success with astigmatism \leq 3.00 D.
- **Patient Experience:**
 - 77% rated overall visual quality as satisfactory or better.
 - 83% rated overall comfort as satisfactory or better.
- **Additional Benefits:** Preserved stereopsis and compatibility across pupil sizes.

This clinical trial validated the NaturalVue Multifocal lens astigmatism correction indication of up to 2.00 D. NaturalVue Multifocal, can correct (vs. mask) an extensive range of astigmatism by enabling both meridians to focus simultaneously due to its patented extended depth of focus design.

Dr. Ashley Tuan, VTI's Chief Medical Officer commented, "Professor Carracedo's study highlights NaturalVue's ability to provide exceptional vision while managing myopia, empowering kids to thrive without compromise."

About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in presbyopia and myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's flagship product is the NaturalVue® (etafilcon A) Enhanced Multifocal 1 Day Contact Lens, an extended depth of focus lens that the Company believes is one of the most significant innovations in the eye care industry in more than 20 years. For more information please visit www.vtivation.com or call +1 844-884-5367, ext. 104.

This information may describe uses for this product, i.e., Myopia Progression Control, which have not been approved by the FDA for use in the United States. It is intended for educational purposes only. NaturalVue® Multifocal is part of an ongoing randomized clinical trial (RCT) studying its effectiveness for myopia progression control.

VTI-RCT-PR9